EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

SQZ Biotechnologies Company (SQZB) fair value: what the stock is really worth

As of Sep 23, 2026: fair value of SQZ Biotechnologies Company $0.02, price $0.02, upside -4.6%, quality 37 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? No
  3. Add to watchlist

Healthcare · US

SB SQZ Biotechnologies Company logo Thin data Sep 23, 2026

SQZ Biotechnologies Company

SQZB · US

Low PriorityFair Value upside is limited and quality is weak.

·Fair value $0.0229 · Fairly valued (−5%)
!Quality 37/100
!Weak Growth (revenue 5y −0.8 %/yr)
!negative free cash flow
!Trails peers (2/6)
!Narrow moat 3/100
!Evidence only low, so the estimate is less certain
!Weak on valuation: 27 out of 100
Watch SQZ Biotechnologies Company for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$15.77 $0.0120 Fair Value $0.0229 Jun 2021 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 23, 2026.

How to read this chart

60‑month range $0.0120 – $15.77 · fair‑value band $0.0214 – $0.0241 · the $0.0240 price screens above the $0.0229 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 23, 2026.

Follow SQZ Biotechnologies in your weekly email

Every Wednesday you see whether SQZ Biotechnologies is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

SQZ Biotechnologies Company, a clinical-stage biotechnology company, develops cell therapies for patients with cancer, infectious diseases, and other serious conditions in Massachusetts.

Show more

SQZ Biotechnologies Company, a clinical-stage biotechnology company, develops cell therapies for patients with cancer, infectious diseases, and other serious conditions in Massachusetts. Its lead product candidate is SQZ-PBMC-HPV, from its SQZ Antigen Presenting Cells platform, which is in a Phase I clinical trial as a monotherapy and in combination with immuno-oncology agents for the treatment of HPV16+ advanced or metastatic solid tumors, including cervical, head-and-neck, anal, penile, vulvar, and vaginal cancer. The company also develops SQZ-AAC-HPV and SQZ-eAPC-HPV, which is in a Phase I clinical trial for the treatment of HPV16+ advanced or metastatic solid tumors in monotherapy and in combinations with immune-oncology agents. Its additional platforms in development are SQZ Activating Antigen Carriers; and SQZ Tolerizing Antigen Carriers. The Company was incorporated in 2013 and is headquartered in Watertown, Massachusetts.

Stock analysis

SQZ Biotechnologies Company (SQZB) currently trades at $0.0240, while our model-based Fair Value estimate is $0.0229, implying the stock looks roughly 4.8% fairly valued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 88/100, which puts the evidence level at low.

Scenario range: $0.0214 (bear) to $0.0241 (bull), the price of $0.0240 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 37/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.

SQZ Biotechnologies Company reported revenue of $12.2M in FY2023 versus $20.1M in FY2019, a compound −11.8%/yr. Reported net income was −$71.6M in FY2023.

Key figures

Market cap $708K · P/S ratio 0.06 · EPS (TTM) $−2.43 · Return on equity −203% · Return on assets (EBIT) −37.6% · Operating margin −501% · Revenue (TTM) $12.1M · Revenue growth (YoY) −94.5%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 22 out of 100 (low confidence).

What moves the price

The share trades about 20% below its 52-week high and 4% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −5% fair-value upside, at −5%, SQZB screens cheaper than that median.

Fair Value models

Bear $0.0214 Fair Value $0.0229 Bull $0.0241
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
NCAV (Graham) $0.0171 $0.0229 $0.0342 51
All 1 models by family
Asset-Based
NCAV (Graham) $0.0171 $0.0229 $0.0342 51

Open the full fair value analysis →

Notify me when SQZB reaches fair value

Put SQZB on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 37/100

Of which business quality 38 · Market factors (momentum, volatility) 37

Profitability 3
Margins and returns on capital today
Quality Growth 30
Are margins and returns improving?
Cashflow 12
Earnings quality: real cash, not paper profit
Fin. Strength 70
Balance sheet, leverage, solvency risk
Investment 100
Disciplined investing over empire-building
Low Volatility 57
Calm price path (market factor)
Momentum 35
Price trend over the last 3–12 months (market factor)
52W Momentum 16
Distance to the 52-week high (market factor)
Net Issuance 38
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−42.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−16.6%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−0.8%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−161.1% (2018) → −498.3% (2023)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2023 is a loss year, no rate is defined from a loss
not computed

Watch SQZB, get fair value alerts →

Compare SQZ Biotechnologies Company with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 649 stocks

Beats the industry median on 2/5 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 38 · Below median
Fair Value upside −5% · Above median
Profitability
Return on assets −41% · Bottom 25%
Growth and dividend
Revenue growth −95% · Bottom 25%

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/S (TTM) 0.06× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)27 · sector 0
FUTURE (revenue growth)0 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)0 · sector 97
DIVIDEND (yield)0 · sector 23

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Vertex Pharmaceuticals Incorporated VRTX $516.34 $567.97 +10%
Regeneron Pharmaceuticals, Inc REGN $801.82 $1,252 +56%
argenx SE ARGX $963.79 $918.60 −5%
Samsung Biologics Co 207940 1,366,000 KRW 1,502,600 KRW +10%
CSL Limited CSL A$179.12 A$197.03 +10%
Alnylam Pharmaceuticals, Inc ALNY $251.65 $218.36 −13%
Royalty Pharma plc RPRX $58.52 $24.22 −59%
BeOne Medicines AG 6160 HK$218.20 HK$169.72 −22%
Celltrion, Inc 068270 177,400 KRW 74,519 KRW −58%
BioNTech SE BNTX $100.87 $63.62 −37%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

SQZ Biotechnologies Company · Fair Value
$0.0229 −5%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "SQZ Biotechnologies Company Fair Value". https://www.fairvalue-calculator.com/stock/SQZB

Frequently asked questions

Is SQZ Biotechnologies Company (SQZB) overvalued or undervalued?
As of Sep 23, 2026, our model estimates a fair value of $0.0229 versus a price of $0.0240, about −5% upside (fairly valued).
What is the fair value of SQZB?
Our model-based fair value for SQZ Biotechnologies Company is $0.0229 (as of Sep 23, 2026), built from audited fundamentals. The current price: $0.0240.
What is the quality score of SQZB?
SQZ Biotechnologies Company has a Quality Score of 37/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for SQZ Biotechnologies Company (SQZB)?
Our model-based price target is the fair value of $0.0229 (as of Sep 23, 2026) from 1 valuation models. Cautious scenario $0.0214, optimistic scenario $0.0241. It is a calculation from audited fundamentals, not an analyst target.
What is the SQZ Biotechnologies Company stock forecast for 2026?
Our models put fair value at $0.0229, about −5% upside versus a price of $0.0240 (fairly valued). Cautious scenario $0.0214, optimistic scenario $0.0241. The calculation is refreshed regularly with new filings.
What is the revenue of SQZ Biotechnologies Company (SQZB)?
SQZ Biotechnologies Company reported trailing-twelve-month revenue of about $12.1M (latest available figure, as of Sep 23, 2026).
What is the intrinsic value of SQZ Biotechnologies Company (SQZB)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For SQZ Biotechnologies Company it is $0.0229 per share (as of Sep 23, 2026), against a price of $0.0240. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is SQZ Biotechnologies Company stock overvalued or undervalued in 2026?
As of Sep 23, 2026, SQZB trades above its calculated fair value: price $0.0240, fair value $0.0229, a gap of about −5% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of SQZB?
No. The price is what the market pays today ($0.0240); the fair value is what the company's own numbers justify ($0.0229). For SQZ Biotechnologies Company the two are $0.0011 per share apart. That gap is exactly why we show both numbers side by side.
How much is SQZ Biotechnologies Company worth?
The market values SQZ Biotechnologies Company at about $708K (market capitalisation, as of Sep 23, 2026). Per share that is $0.0240; our models calculate a fair value of $0.0229 per share.
What do the bullish and bearish scenarios say about SQZB?
Our models span a range for SQZ Biotechnologies Company: cautious scenario $0.0214, base $0.0229, optimistic $0.0241 per share (as of Sep 23, 2026, price $0.0240). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of SQZ Biotechnologies Company (SQZB)?
Balance-sheet figures for SQZ Biotechnologies Company (as of Sep 23, 2026): return on equity −203.4%. They feed the Quality Score of 37/100, which measures business quality independently of the share price.
How far is SQZB from its 52-week high?
SQZ Biotechnologies Company trades at $0.0240, about 20% below its 52-week high of $0.0300 and 4% above the low of $0.0230 (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of $0.0229 is for.
Which stocks are comparable to SQZ Biotechnologies Company?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, Samsung Biologics Co, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is SQZ Biotechnologies Company stock attractive at the current price?
The data as of Sep 23, 2026: price $0.0240, calculated fair value $0.0229 (−5%), Quality Score 37/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of SQZB calculated?
We run SQZ Biotechnologies Company through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $0.0229, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0 % above its aggregate fair value. SQZ Biotechnologies Company itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of SQZ Biotechnologies Company (SQZB)?
The closing price on Sep 23, 2026 was $0.0240. Our model-based fair value is $0.0229, about −5% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with SQZ Biotechnologies Company right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. The models converge in a tight band ($0.0214 to $0.0241), unusually little disagreement for a valuation. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of SQZ Biotechnologies Company

How large is the market capitalisation of SQZ Biotechnologies Company (SQZB)?
The market capitalisation of SQZ Biotechnologies Company is $708K. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of SQZ Biotechnologies Company (SQZB)?
The price-to-sales ratio of SQZ Biotechnologies Company is 0.06 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of SQZ Biotechnologies Company (SQZB)?
Earnings per share at SQZ Biotechnologies Company are $−2.43. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of SQZ Biotechnologies Company (SQZB)?
The return on equity (ROE) of SQZ Biotechnologies Company is −203% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of SQZ Biotechnologies Company (SQZB)?
On an EBIT basis the return on assets of SQZ Biotechnologies Company is −37.6% (avg 4y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of SQZ Biotechnologies Company (SQZB)?
The operating margin of SQZ Biotechnologies Company is −501% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at SQZ Biotechnologies Company (SQZB)?
Revenue at SQZ Biotechnologies Company is growing −94.5% versus a year earlier (3y avg −16.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does SQZ Biotechnologies Company (SQZB) generate?
The free cash flow of SQZ Biotechnologies Company is −$74.5M (fiscal year 2023). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does SQZ Biotechnologies Company (SQZB) hold?
SQZ Biotechnologies Company holds more cash than debt, $29.3M net (fiscal year 2022). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch SQZ Biotechnologies Company in the live analysis

One click puts SQZ Biotechnologies Company on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.